Here's What Else Gilead Sciences Gets by Buying Kite Pharma

Here's What Else Gilead Sciences Gets by Buying Kite Pharma

Gilead Sciences' (NASDAQ: GILD) planned $11.9 billion acquisition of Kite Pharma (NASDAQ: KITE) nets it axi-cel, a CAR-T therapy that's already under FDA review. However, axi-cel isn't the only intriguing therapy in development at Kite Pharma. Gilead Sciences also gets its hand on next-generation TCR-targeting drugs that could someday change how doctors treat patients with solid tumor cancers.

Gilead Sciences has been planning for years to make a big splash in oncology, and on Monday, it announced that it is acquiring Kite Pharma for nearly $12 billion in cash.

Image source: Getty Images.

Continue reading

Source: Fool.com